SG11201805380YA - Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy - Google Patents
Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapyInfo
- Publication number
- SG11201805380YA SG11201805380YA SG11201805380YA SG11201805380YA SG11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA SG 11201805380Y A SG11201805380Y A SG 11201805380YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pennsylvania
- formula
- psma
- philadelphia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Nuclear Medicine (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 6 July 2017 (06.07.2017) WIPOIPCT (10) International Publication Number WO 2017/116994 A1 (51) International Patent Classification: G01N33/60 (2006.01) C12Q 1/37{2006.01) G01N33/68 (2006.01) (21) International Application Number: PCT/US2016/068327 (22) International Filing Date: 22 December 2016 (22.12.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/273,786 31 December 2015 (31.12.2015) US 15/385,490 20 December 2016 (20.12.2016) US (71) Applicant: FIVE ELEVEN PHARMA INC. [US/US]; 3700 Market St. Suite 305, Philadelphia, Pennsylvania 19104 (US). (72) Inventors: KUNG, Hank F.; 232 N. Highland Road, Springfield, Pennsylvania 19064 (US). PLOESSL, Karl; 1525 Delaware Ave. #3, Wilmington, Delaware 19806 (US). CHOI, Seok Rye; 52 Andrew Court, Aston, Pennsylvania 19014 (US). ZHA, Zhihao; 221 S. 44th Street, Apt. 2-F, Philadelphia, Pennsylvania 19104 (US). WU, Zehui; 503S 41st Street, Apt. 302, Philadelphia, Pennsylvania 19104 (US). (74) Agents: COVERT, John M. et al.; Sterne, Kessler, Gold stein & Fox PLLC, 1100 New York Avenue, NW, Wash ington, District of Columbia 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) •t 0\ 0\ o CJ (54) Title: UREA-BASED PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITORS FOR IMAGING AND THER APY (57) : The present invention relates to compounds according to Formula I and Formula IV. These compounds display very good binding affinities to the PSMA binding sites. They can be labeled with [68Ga]GaC13 with high yields and excellent radiochem - ical purity. The present invention also relates to pharmaceutical compositions comprising a pharmaceutical acceptable carrier and a compound of Formula I or Formula IV, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562273786P | 2015-12-31 | 2015-12-31 | |
| US15/385,490 US10688200B2 (en) | 2015-12-31 | 2016-12-20 | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| PCT/US2016/068327 WO2017116994A1 (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805380YA true SG11201805380YA (en) | 2018-07-30 |
Family
ID=59225798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805380YA SG11201805380YA (en) | 2015-12-31 | 2016-12-22 | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10688200B2 (en) |
| EP (1) | EP3397968B1 (en) |
| JP (1) | JP6850027B2 (en) |
| KR (1) | KR20180098373A (en) |
| CN (1) | CN108541302B (en) |
| AU (2) | AU2016380151A1 (en) |
| CA (1) | CA3010295C (en) |
| DK (1) | DK3397968T3 (en) |
| EA (1) | EA201891544A1 (en) |
| HK (1) | HK1255215A1 (en) |
| IL (1) | IL260342A (en) |
| MX (1) | MX2018008168A (en) |
| SG (1) | SG11201805380YA (en) |
| WO (1) | WO2017116994A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20237497B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
| RU2021115958A (en) * | 2016-03-22 | 2021-07-12 | Дзе Джонс Хопкинс Юниверсити | PROSTATIC SPECIFIC MEMBRANE ANTIGEN-TARGET HIGH AFFINITY DRUGS FOR ENDORADIOTHERAPY FOR PROSTATE CANCER |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| EP3630733A4 (en) * | 2017-05-30 | 2021-03-17 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| LT3723815T (en) | 2017-12-11 | 2022-07-25 | Technische Universität München | Psma ligands for imaging and endoradiotherapy |
| US20190184040A1 (en) * | 2017-12-15 | 2019-06-20 | Wisconsin Alumni Research Foundation | Targeted Macrocyclic Agents for Dual Modality PET and MRI Imaging of Cancer |
| MX2018003175A (en) * | 2018-03-14 | 2019-09-16 | Instituto Nac De Investigaciones Nucleares | 177lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen. |
| CN109438517B (en) * | 2018-12-27 | 2021-01-08 | 北京久杰净化工程技术有限公司 | Complex of bifunctional linking agent coordinated with carbonyl metal core and preparation method thereof |
| WO2020220023A1 (en) * | 2019-04-26 | 2020-10-29 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
| WO2020252598A1 (en) | 2019-06-21 | 2020-12-24 | Provincial Health Services Authority | Radiolabeled compounds targeting the prostate-specific membrane antigen |
| CN115380117A (en) * | 2020-02-18 | 2022-11-22 | 恩多塞特公司 | Methods of treating PSMA-expressing cancers |
| WO2022072292A1 (en) * | 2020-10-01 | 2022-04-07 | Cornell University | Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands |
| CN112358422B (en) * | 2020-10-16 | 2023-06-23 | 中国辐射防护研究院 | Preparation method of novel chelating agent NBED |
| US20240158420A1 (en) * | 2021-03-17 | 2024-05-16 | Five Eleven Pharma, Inc | [18f]a1f labeled psma targeting molecular probe and preparation method therefor |
| CN113372285B (en) * | 2021-05-28 | 2024-06-18 | 西南医科大学附属医院 | Prostate specific membrane antigen inhibitor, radionuclide marker, preparation method and application thereof |
| CN114436905A (en) * | 2022-01-24 | 2022-05-06 | 攀枝花学院 | Purification method of 3-aldehyde-4-hydroxy methyl phenylacetate |
| WO2023143612A1 (en) * | 2022-01-30 | 2023-08-03 | 晶核生物医药科技(南京)有限公司 | Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative |
| CN114874122A (en) * | 2022-05-31 | 2022-08-09 | 南京航空航天大学 | Novel small molecule inhibitor and preparation method and application thereof |
| CN116547293A (en) * | 2023-02-02 | 2023-08-04 | 北京师范大学 | Radioactive metal complex for targeting prostate specific membrane antigen and labeled ligand thereof |
| WO2023231452A1 (en) * | 2023-02-14 | 2023-12-07 | 北京师范大学 | Psma-targeting radioactive metal complex containing nitro aromatic heterocyclic group and preparation thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060523A1 (en) | 2002-01-10 | 2003-07-24 | Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
| CA2733790A1 (en) | 2008-08-20 | 2010-02-25 | Ensemble Discovery Corporation | Macrocyclic compounds for inhibition of tumor necrosis factor alpha |
| US9446157B2 (en) * | 2011-06-15 | 2016-09-20 | Cancer Targeted Technology Llc | Chelated PSMA inhibitors |
| JP5843338B2 (en) * | 2011-08-05 | 2016-01-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | Radiolabeled prostate-specific membrane antigen inhibitor |
| CN104203942B (en) * | 2011-11-30 | 2017-04-12 | 约翰霍普金斯大学 | Homomultivalent and heteromultivalent inhibitors of prostate specific membrane antigen (PMSA) and uses thereof |
| JP6892218B2 (en) * | 2012-11-15 | 2021-06-23 | エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． | How to treat diseases caused by drug delivery conjugates and PSMA-expressing cells |
| CN105025933B (en) * | 2013-01-14 | 2019-03-26 | 分子制药洞察公司 | Triazine radiomimetic drug and radio-contrast agent |
| US10406246B2 (en) | 2013-10-17 | 2019-09-10 | Deutsches Kresbsforschungszentrum | Double-labeled probe for molecular imaging and use thereof |
| EP2862857A1 (en) * | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| GEP20237497B (en) | 2013-10-18 | 2023-04-10 | Deutsches Krebsforsch | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN105849568B (en) * | 2013-11-14 | 2018-05-04 | 恩多塞特公司 | Compound for positron emission fault art |
| EP3536345A1 (en) * | 2014-05-06 | 2019-09-11 | The Johns Hopkins University | Metal/radiometal-labeled psma inhibitors for psma-targeted imaging and radiotherapy |
| US10688200B2 (en) | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
-
2016
- 2016-12-20 US US15/385,490 patent/US10688200B2/en active Active
- 2016-12-22 AU AU2016380151A patent/AU2016380151A1/en not_active Abandoned
- 2016-12-22 EP EP16882430.8A patent/EP3397968B1/en active Active
- 2016-12-22 WO PCT/US2016/068327 patent/WO2017116994A1/en active Application Filing
- 2016-12-22 MX MX2018008168A patent/MX2018008168A/en unknown
- 2016-12-22 CA CA3010295A patent/CA3010295C/en active Active
- 2016-12-22 EA EA201891544A patent/EA201891544A1/en unknown
- 2016-12-22 JP JP2018534552A patent/JP6850027B2/en active Active
- 2016-12-22 SG SG11201805380YA patent/SG11201805380YA/en unknown
- 2016-12-22 DK DK16882430.8T patent/DK3397968T3/en active
- 2016-12-22 CN CN201680079844.7A patent/CN108541302B/en active Active
- 2016-12-22 KR KR1020187021593A patent/KR20180098373A/en not_active Application Discontinuation
-
2018
- 2018-06-28 IL IL260342A patent/IL260342A/en unknown
- 2018-11-09 HK HK18114343.5A patent/HK1255215A1/en unknown
-
2023
- 2023-06-13 AU AU2023203682A patent/AU2023203682A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA201891544A1 (en) | 2018-11-30 |
| DK3397968T3 (en) | 2021-11-01 |
| EP3397968A1 (en) | 2018-11-07 |
| AU2023203682A1 (en) | 2023-07-06 |
| CN108541302A (en) | 2018-09-14 |
| EP3397968B1 (en) | 2021-09-29 |
| HK1255215A1 (en) | 2019-08-09 |
| CA3010295A1 (en) | 2017-07-06 |
| WO2017116994A1 (en) | 2017-07-06 |
| US20170189568A1 (en) | 2017-07-06 |
| AU2016380151A1 (en) | 2018-07-19 |
| CA3010295C (en) | 2023-09-26 |
| KR20180098373A (en) | 2018-09-03 |
| MX2018008168A (en) | 2019-02-20 |
| JP6850027B2 (en) | 2021-03-31 |
| CN108541302B (en) | 2023-02-14 |
| EP3397968A4 (en) | 2019-11-27 |
| US10688200B2 (en) | 2020-06-23 |
| JP2019508374A (en) | 2019-03-28 |
| IL260342A (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201900799XA (en) | Pyridopyrimdinone cdk2/4/6 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201808582RA (en) | Pyrrolotriazine compounds as tam inhibitors | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805645QA (en) | Lsd1 inhibitors | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib |